10/ 602,214

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online

NEWS EXPRESS	JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:09:46 ON 22 APR 2005

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

10/ 602,214

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:09:58 ON 22 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 APR 2005 HIGHEST RN 848979-49-7
DICTIONARY FILE UPDATES: 21 APR 2005 HIGHEST RN 848979-49-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10602214a.str



chain nodes :
12 18 19 20 21 24 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 13 14 15 16 17
chain bonds :
1-6 2-24 4-12 18-19 19-20 19-21
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 13-14 13-17 14-15
15-16 16-17
exact/norm bonds :
1-2 1-5 1-6 2-24 4-5
exact bonds :
2-3 3-4 4-12 13-14 13-17 14-15 15-16 16-17 18-19
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 19-20 19-21
isolated ring systems :
containing 1 : 6 : 13 :

G1:[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 24:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 [@1],[@2]

10/ 602,214

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10602214b.str



chain nodes :
7 8 9 10 19 21
ring nodes :
2 3 4 5 6 13 14 15 16 17 18
chain bonds :
2-7 6-13 7-8 8-9 8-10 14-21
ring bonds :
2-3 2-6 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
2-3 2-6 3-4 5-6 6-13 7-8 8-9 8-10
exact bonds :
2-7 4-5 14-21
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 2 : 13 :

G1

Match level :
2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 21:CLASS

L2 STRUCTURE UPLOADED

=> d l2
L2 HAS NO ANSWERS
L2 STR



G1

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sample
SAMPLE SEARCH INITIATED 16:10:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      0 TO ITERATE

100.0% PROCESSED       0 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L3            0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 16:11:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      8 TO ITERATE

100.0% PROCESSED       8 ITERATIONS                              1 ANSWERS
SEARCH TIME: 00.00.01

L4            1 SEA SSS FUL L1

=> s l2 sample
SAMPLE SEARCH INITIATED 16:11:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     27 TO ITERATE

100.0% PROCESSED      27 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          229 TO      851
PROJECTED ANSWERS:               0 TO        0

L5            0 SEA SSS SAM L2
```

10/ 602,214

```
=> s l2 ful
FULL SEARCH INITIATED 16:11:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    350 TO ITERATE

100.0% PROCESSED     350 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L6            0 SEA SSS FUL L2

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     323.09     323.30

FILE 'CAPLUS' ENTERED AT 16:11:45 ON 22 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 22 Apr 2005  VOL 142 ISS 18
FILE LAST UPDATED: 21 Apr 2005  (20050421/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 16:09:46 ON 22 APR 2005)

     FILE 'REGISTRY' ENTERED AT 16:09:58 ON 22 APR 2005
L1              STRUCTURE UPLOADED
L2              STRUCTURE UPLOADED
L3            0 S L1 SAMPLE
L4            1 S L1 FUL
L5            0 S L2 SAMPLE
L6            0 S L2 FUL

     FILE 'CAPLUS' ENTERED AT 16:11:45 ON 22 APR 2005

=> s l4
L7            6 L4

=> d l7 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 6 ANSWERS - CONTINUE? Y/(N):y
```

L7 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:566937 CAPLUS
DOCUMENT NUMBER: 142:219198
TITLE: Discovery of 1-(3'-Aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor
AUTHOR(S): Quan, Mimi L.; Lam, Patrick Y. S.; Han, Qi; Pinto, Donald J. P.; He, Ming Y.; Li, Renhua; Ellis, Christopher D.; Clark, Charles G.; Teleha, Christopher A.; Sun, Jung-Hui; Alexander, Richard S.; Bai, Steve; Luettgen, Joseph M.; Knabb, Robert M.; Wong, Pancras C.; Wexler, Ruth R.
CORPORATE SOURCE: Discovery Chemistry Pharmaceutical Research Institute, Bristol-Myers Squibb Co., Princeton, NJ, 08543-5400, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(6), 1729-1744
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P1 ligand resulted in compds. with improved selectivity for factor Xa relative to trypsin and plasma kallikrein. Further optimization of the P4 moiety led to compds. with enhanced permeability and reduced protein binding. The SAR and pharmacokinetic profile of this series of compds. is described. These efforts culminated in 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxamide (I), a potent, selective, and orally bioavailable inhibitor of factor Xa. On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compound was selected for clin. development as razaxaban (DPC 906, BMS-561389).
IT 218301-47-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of razaxaban and related compds. as potent, selective, and orally bioavailable factor Xa inhibitors)
RN 218301-47-4 CAPLUS
CN Benzonitrile, 2-fluoro-5-[5-(2-furanyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:454067 CAPLUS
DOCUMENT NUMBER: 139:36524
TITLE: Preparation of novel N-[4-(1H-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as factor Xa inhibitors
INVENTOR(S): Quan, Mimi L.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003047517	A2	20030612	WO 2002-US38168	20021126
WO 2003047517	A3	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003144287	A1	20030731	US 2002-302184	20021122
→ US 6730689	B2	20040504		
EP 1460996	A2	20040929	EP 2002-789922	20021126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:			US 2001-336972P P	20011204
			WO 2002-US38168 W	20021126

OTHER SOURCE(S): MARPAT 139:36524
GI

6730689

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB N-[4-(1H-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides of formula I [R = H, alkyl; R1 = H, acyl, etc.] and derivs. thereof are prepared which are useful as inhibitors of factor Xa. Thus, II was prepared in several steps. The prepared compds. had Ki values of ≤ 10 μM against human factor Xa.
IT 218301-47-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazolylphenyl pyrazolecarboxamide derivs. as factor Xa inhibitors)
RN 218301-47-4 CAPLUS
CN Benzonitrile, 2-fluoro-5-[5-(2-furanyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:240767 CAPLUS
DOCUMENT NUMBER: 136:281142
TITLE: Efficient process for the preparation of a factor Xa inhibitor
INVENTOR(S): Sunkara, Hari Babu; Yang, Yali
PATENT ASSIGNEE(S): E. I. Du Pont de Nemours & Co., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024690	A2	20020328	WO 2001-US28406	20010912
WO 2002024690	C1	20020808		
WO 2002024690	A3	20030925		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2424576	AA	20020328	CA 2001-2424576	20010912
AU 2001092612	A5	20020402	AU 2001-92612	20010912
EP 1366045	A2	20031203	EP 2001-972987	20010912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004529853	T2	20040930	JP 2002-529100	20010912
US 2002061917	A1	20020523	US 2001-960040	20010921
US 6667332	B2	20031223		
TW 593314	B	20040621	TW 2001-90123363	20010921
NO 2003001308	A	20030507	NO 2003-1308	20030321
US 2003212117	A1	20031113	US 2003-431265	20030507
US 6747158	B2	20040608		
BG 107813	A	20040130	BG 2003-107813	20030513
US 2004198787	A1	20041007	US 2004-826099	20040415

PRIORITY APPLN. INFO.:
US 2000-234622P P 20000922
WO 2001-US28406 W 20010912
US 2001-960040 A3 20010921
US 2003-431265 A3 20030507

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to the process for the preparation of the compound
I.HCl, useful as a factor Xa inhibitor, from compound II and intermediates

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
useful therein. The improved process involves reacting unpurified II with maleic acid in EtOAc, pptg. the resulting compd. I by adding BuCl to the reaction mixt., reacting I with HONHCOMe in a solvent in the presence of K2CO3, Na2CO3, KHCO3, NaHCO3, KF, NaOH, or KOH, and contacting the resulting product with HCl.

IT 218301-47-4P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(precursor; aminomethylimidazolophenylaminocarbonylbenzisoxazolyltrifluoromethylpyrazole factor Xa inhibitor manuf)

RN 218301-47-4 CAPLUS
CN Benzonitrile, 2-fluoro-5-[5-(2-furanyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:39605 CAPLUS
DOCUMENT NUMBER: 136:102380
TITLE: Preparation of novel guanidine mimics as factor Xa inhibitors
INVENTOR(S): Lam, Patrick Y.; Clark, Charles G.; Dominguez, Celia; Fevig, John M.; Han, Qi; Li, Renhua; Pinto, Donald J. P.; Pruitt, James R.; Quan, Mimi L.
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
SOURCE: U.S., 117 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6339099	B1	20020115	US 1998-99358	19980618
US 2002025963	A1	20020228	US 2001-924381	20010808
US 2003069258	A1	20030410	US 2002-98994	20020313
US 2004063772	A1	20040401	US 2003-602214	20030624

PRIORITY APPLN. INFO.:
US 1997-50265P P 19970620
US 1998-99358 A3 19980618
US 2001-924381 B1 20010808

OTHER SOURCE(S): MARPAT 136:102380
GI



II



II

AB The title compds. [I; ring D = 5-membered aromatic system containing from 1-2
heteroatoms selected from N, O, S; ring D is substituted with 0-2 R groups; ring E contains 0-2 N atom and is substituted by 0-1 R groups; R = Cl, F, Br, I, OH, alkoxy, amino(alkyl), (alkyl)amino; Z = bond, alkylene, (CH2)rO(CH2)r, (CH2)rNR3(CH2)r, (CH2)rC(O)(CH2)r, (CH2)rC(O)O(CH2)r, (CH2)rOC(O)(CH2)r, (CH2)rC(O)NR3(CH2)r, etc. provided that Z does not form

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
a N-N, N-O, N-S, NCH2N, NCH2O, or NCH2S bond with ring M or group A; R1a-1b = H, alk(en)yl, aminoalkyl, alkoxy, alternatively, R1a-1b, when attached to adjacent carbon atoms, together with the atoms to which they are attached form a 5-8 membered (un)satd. ring (un)substituted and which contains from 0-2 heteroatoms selected from the group consisting of N, O, and S; alternatively, when Z is C(O)NH and R1a is attached to a ring carbon adjacent to Z, then R1a is a C(O) which replaces the amide hydrogen of Z to form a cyclic imide; R3 = H, alkyl, phenyl; A = (un)substituted carbocyclic, 5-10 membered heterocyclic system contg. 1-4 heteroatoms selected from N, O, S; B = H, Y, X-Y; X = sulfonylalkyl, alkylsulfonyl, sulfonamide, etc.; Y = alkylamino, provided that X-Y does not form a N-N, O-N or S-N bond, carbocyclic group, 5-10 membered heterocyclic r = 0-3], inhibitors of factor Xa which are useful in treating and preventing a thromboembolic disorder, were prepd. and formulated. Thus, a multi-step synthesis of the title compd. II, starting with 7-aminoisoquinoline, was described. A no. of compds. I were found to exhibit a Ki of ≤ 15 μM against factor Xa.

IT 218301-47-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel guanidine mimics as factor Xa inhibitors)

RN 218301-47-4 CAPLUS
CN Benzonitrile, 2-fluoro-5-[5-(2-furanyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:364680 CAPLUS
DOCUMENT NUMBER: 133:119881
TITLE: Palladium-catalyzed cyanation reactions of aryl chlorides
AUTHOR(S): Jin, Fuqiang; Confalone, Pat N.
CORPORATE SOURCE: DuPont Experimental Station, Chemical Process R and D, The DuPont Pharmaceuticals Company, Wilmington, DE, 19880-0336, USA
SOURCE: Tetrahedron Letters (2000), 41(18), 3271-3273
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:119881

AB We have discovered an efficient cyanation of aryl chlorides which employs Pd2(dba)3, dppf and Zn as the catalyst and Zn(CN)2 as the cyanide source. Both electron-deficient and electron-rich aryl chlorides are effectively cyanated under these conditions. This discovery represents the first successful palladium-catalyzed cyanation of both electron-deficient and electron-rich aryl chlorides.

IT 218301-47-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(palladium-catalyzed cyanation of aryl chlorides)

RN 218301-47-4 CAPLUS
CN Benzonitrile, 2-fluoro-5-[5-(2-furanyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:9833 CAPLUS
DOCUMENT NUMBER: 130:66494
TITLE: Preparation of novel guanidine mimics as factor Xa inhibitors
INVENTOR(S): Lam, Patrick Y.; Clark, Charles G.; Dominguez, Celia; Fevig, John Matthew; Han, Qi; Li, Renhua; Pinto, Donald Joseph-Phillip; Pruitt, James Russell; Quan, Mimi Lifen
PATENT ASSIGNEE(S): The Du Pont Merck Pharmaceutical Company, USA
SOURCE: PCT Int. Appl., 268 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857951	A1	19981223	WO 1998-US12680	19980618
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ZA 9805247	A	19991217	ZA 1998-5247	19980617
CA 2291442	AA	19981223	CA 1998-2291442	19980618
AU 9879768	A1	19990104	AU 1998-79768	19980618
AU 756755	B2	20030123		
EP 991638	A1	20000412	EP 1998-930361	19980618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9810137	A	20000808	BR 1998-10137	19980618
EE 9900583	A	20000815	EE 1999-583	19980618
EE 4153	B1	20031015		
JP 2002505686	T2	20020219	JP 1999-504785	19980618
NZ 502370	A	20021025	NZ 1998-502370	19980618
TW 544453	B	20030801	TW 1998-87109910	19980819
NO 9905965	A	19991203	NO 1999-5965	19991203
MX 9911908	A	20000531	MX 1999-11908	19991216
LV 12496	B	20010120	LV 1999-178	19991216
LT 4705	B	20000925	LT 1999-147	19991217
PRIORITY APPLN. INFO.:			US 1997-878884 A	19970619
			WO 1998-US12680 W	19980618
OTHER SOURCE(S):	MARPAT 130:66494			

GI

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I II

AB The title compds. [I; rings D-E represent guanidine mimics; ring D = CH2N:CH, CH2CH2N:CH, a 5-6 membered aromatic system containing 0-2 heteroatoms selected form the group N, O, and S; ring D is substituted with 0-2 R (substituents), provided that when ring D is unsubstituted, it contains at least one heteroatom; ring E contains 0-2 N atom and is substituted by 0-1 R; R = halo, OH, C1-3 alkoxy, etc.; M = (un)substituted pyrazole, imidazole, tetrazole, etc.], inhibitors of factor Xa which are useful in treating and preventing a thromboembolic disorder, were prepared and formulated. Thus, a multi-step synthesis of the title compound II, starting with 7-aminoisoquinoline, was described. A number of compds. I were found to exhibit a Ki of ≤ 15 μM against factor Xa.

IT 218301-47-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel guanidine mimics as factor Xa inhibitors)

RN 218301-47-4 CAPLUS
CN Benzonitrile, 2-fluoro-5-[5-(2-furanyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/ 602,214

```
=> s l12 and dimethylaminomethyl
          4871 DIMETHYLAMINOMETHYL
L13          0 L12 AND DIMETHYLAMINOMETHYL

=> s l12 and methanamine
          2316 METHANAMINE
L14          1 L12 AND METHANAMINE

=> d l14 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
```

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:10978 CAPLUS
DOCUMENT NUMBER: 132:160832
TITLE: A novel approach to the analysis of substituent effects: quantitative description of ionization energies and gas basicity of amines
AUTHOR(S): Cherkasov, Artem R.; Jonsson, Mats; Galkin, Vladimir
CORPORATE SOURCE: Department of Chemistry, Royal Institute of Technology, Stockholm, Swed.
SOURCE: Journal of Molecular Graphics & Modelling (1999), 17(1), 28-42
CODEN: JMGMFI; ISSN: 1093-3263
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In this work, a new topol. approach based on simple matrix algebra is introduced to explore substituent effects at the level of atomic additivity in the absence of significant resonance contributions. In the framework of the suggested method, all atoms are classified according to element and valence state. The sums of the inverse squared distances between the substituent atoms and the reaction center of the mol. are used as operational parameters in the present method. The approach implies atomic level of consideration of inductive and steric effects and allows for quantification of substituent effects without the use of pre-established group substituent consts. The practical application of the model is illustrated by the quant. interpretation of ionization energies and gas basicity of a broad range of amines. Further development of the elaborated approach is also discussed.

IT 1801-14-5
RL: PRP (Properties)
(quant. description of ionization energies and gas basicity of amines)

RN 1801-14-5 CAPLUS
CN Benzenamine, 2,3,4,5,6-pentafluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/ 602,214

```
=> s l12 amd imidazol?
MISSING OPERATOR L12 AMD
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l12 and imidazol?
         88559 IMIDAZOL?
L15          2 L12 AND IMIDAZOL?

=> d l15 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y
```

L15 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:617590 CAPLUS
DOCUMENT NUMBER: 139:292201
TITLE: Diversity Synthesis via C-H Bond Functionalization: Concept-Guided Development of New C-Arylation Methods for Imidazoles
AUTHOR(S): Sezen, Bengue; Sames, Dalibor
CORPORATE SOURCE: Department of Chemistry, Columbia University, New York, NY, 10027, USA
SOURCE: Journal of the American Chemical Society (2003), 125(35), 10580-10585
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:292201

AB Herein, the concept of systematic derivatization of a structural motif via C-H bond functionalization was formulated. This concept may not only serve as a blueprint for new strategies in diversity synthesis but also provide systematic guidance for the identification of unsolved and important synthetic challenges. To illustrate this point, 2-phenylimidazole was selected as the core motif for this study, a choice inspired by numerous azole-based synthetics, including pharmaceuticals (compound SB 202190), and also fluorescent and chemiluminescent probes. It was possible to show that systematic and comprehensive arylation of the 2-phenylimidazole core was feasible, and in the context of this study new arylation methods were developed. The direct 4-arylation of free 2-phenylimidazole was achieved with iodoarenes as the aryl donors in the presence of palladium catalyst (Pd/Ph3P) and magnesium oxide as the base. A complete switch from C-4 to C-2' arylation was accomplished using a ruthenium catalyst [CpRu(Ph3P)2Cl] and Cs2CO3. The corresponding transformations for (N,2)-diphenylimidazole (C-5 and C-2' arylation) were accomplished via the palladium-based method [Pd(OAc)2/Ph3P/Cs2CO3] and a rhodium-catalyzed procedure [Rh(acac)(CO)2/Cs2CO3], resp. All of the arylation methods described herein demonstrated broad synthetic scope, high efficiency, and exclusive selectivity. Furthermore, these new methods proved to be orthogonal to one another and applicable to sequential arylation schemes. With these methods in hand, arrays of arylated imidazoles may now be accessed in a direct manner from 2-phenylimidazole. This strategy stands in sharp contrast to a traditional approach, wherein a distinct and multistep synthesis would be required for each analog.

IT 403-46-3, 4-Fluoro-N,N-dimethylaniline
RL: RCT (Reactant); RACT (Reactant or reagent)
(diversity synthesis via carbon-hydrogen bond functionalization; concept-guided development of carbon arylation methods for imidazoles)

RN 403-46-3 CAPLUS
CN Benzenamine, 4-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)



L15 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:376831 CAPLUS
DOCUMENT NUMBER: 138:385442
TITLE: Preparation of (anilino)quinazolines as antitumor agents
INVENTOR(S): Hennequin, Laurent Francois Andre; Kettle, Jason Grant; Pass, Martin; Bradbury, Robert Hugh
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 275 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040109	A2	20030515	WO 2002-GB4932	20021031
WO 2003040109	A3	20030626		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1444211	A2	20040811	EP 2002-774961	20021031
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013843	A	20040831	BR 2002-13843	20021031
US 2005054662	A1	20050310	US 2004-494388	20041001
PRIORITY APPLN. INFO.:			GB 2001-26433 A	20011103
			WO 2002-GB4932 W	20021031

OTHER SOURCE(S): MARPAT 138:385442
GI



AB Title compds. I [wherein m = 0-2; n = 1-2; L = a bond or [C(R22)2]n; R1 = halo, CF3, CN, NC, NO2, OH, SH, NH2, CHO, CO2H, CONH2, or (un)substituted alkyl(oxy), alkenyl(oxy), alkynyl(oxy), alkylthio, alkylsulfinyl, alkylsulfonyl, (di)alkylamino, alkoxycarbonyl, (di)alkylcarbamoyl, alkanoyl(oxy), (alkyl)alkanoylamino, (alkyl)alkenoylamino, (alkyl)alkynoylamino, (di)alkylsulfamoyl, (alkyl)alkanesulfonylamino, or Q3X1; or (R1)m = alkylenedioxy; with the proviso that adjacent alkylene C atoms within a R1 substituent are optionally interrupted by O, S, SO, SO2, NR5, CO, CHOR5, CONR5, NR5CO, SO2NR5, NR5SO2, CH=CH, or C.tplbond.C; R2 = H; R3, R4, R5, R11, R12, and R22 = independently H or alkyl; Q1 and Q3 = independently (un)substituted (hetero)aryl(alkyl), cycloalkyl(alkyl), cycloalkenyl(alkyl), or heterocyclyl(alkyl); with the proviso that adjacent alkylene C atoms within the Q1Z group are optionally interrupted by O, S, SO, SO2, NR12, CO, CHOR12, CONR12, NR12CO, SO2NR12, NR12SO2, CH=CH, or C.tplbond.C; Q2 = (un)substituted Ph, bicyclic (hetero)aryl, or bicyclic heterocyclyl; X1 = a bond, O, S, SO, SO2, NR4, CO, CHOR4, CONR4, NR4CO, SO2NR4, NR4SO2, OC(R4)2, SC(R4)2, or NR4C(R4)2; Z = a bond, O, S, SO, SO2, NR11, CO, CHOR11, CONR11, NR11CO, SO2NR11, NR11SO2, OC(R11)2, SC(R11)2, or NR11C(R11)2; and pharmaceutically acceptable salts thereof] were prepd. for use in the prevention or treatment of tumors which are sensitive to inhibition of erbB receptor tyrosine kinases. For example, coupling of 3-(R)-(+)-dimethylaminopyrrolidine with 3,4-dihydro-5-hydroxy-7-fluoroquinazolin-4-one=CF3CO2H in NMP gave the pyrrolidinylquinazolinone (41%). Addn. of chloromethyl pivalate in the presence of NaH in DMF afforded the 3-substituted deriv. (62%), which was condensed with 4-hydroxy-N-methylpiperidine using PPh3 and di-tert-Bu azodicarboxylate in DCM to give the piperidinyloxyquinazolinone (77%). Deprotection (66%) using NH3 in MeOH, followed by chlorination with POCl3 and di-disopropylethylamine in dichloroethane provided 4-chloro-7-(3-(R)-dimethylaminopyrrolidin-1-yl)-5-(1-methylpiperidin-4-yloxy)quinazoline (81%). Coupling of the chloroquinazoline with 3-bromoaniline in the presence of HCl and IPA in dioxane yielded II•HCl (43%). The biol. activity of the example compds. was assessed in five assays. Thus, I inhibited the phosphorylation of a tyrosine-contg. polypeptide substrate by epidermal growth factor receptor (EGFR) kinase, erbB2 kinase, and erbB4 kinase with IC50 values in the range of 0.001 μM - 10 μM. I also inhibited the proliferation of both human naso-pharyngeal carcinoma KB cells and non-neoplastic epithelial H16N-2 cells with IC50 values in the range 0.001 μM - 20 μM. In addn., I inhibited the growth of colorectal adenocarcinoma LoVo and human mammary carcinoma BT-474 tumor cell xenografts in vivo with activities in the range of 1 mg/kg/day to 200 mg/kg/day with no physiol. unacceptable toxicity at the ED.

IT 525590-51-6P, 4-(3-Chloro-4-fluoroanilino)-7-(3-(R)-dimethylaminopyrrolidin-1-yl)-5-(1-methylpiperidin-4-yloxy)quinazoline
525592-03-4P, 4-(3-Chloro-4-fluoroanilino)-7-[3-[N-(2-dimethylaminoethyl)-N-methylamino]propoxy]-5-(1-methylpiperidin-4-yloxy)quinazoline 525592-14-7P, 4-(3-Chloro-4-fluoroanilino)-7-[2-[N-(2-dimethylaminoethyl)-N-methylamino]ethoxy]-5-(1-methylpiperidin-4-yloxy)quinazoline 525592-20-5P, 4-(3-Chloro-4-fluoroanilino)-7-(2-(3-dimethylaminopyrrolidin-1-yl)ethoxy)-5-(1-methylpiperidin-4-yloxy)quinazoline 525592-29-4P, 4-(3-Chloro-4-fluoroanilino)-7-[3-[N-(2-dimethylaminoethyl)-N-methylamino]propoxy]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 525592-35-2P, 4-(3-Chloro-4-fluoroanilino)-7-(3-(3-dimethylaminopyrrolidin-1-yl)propoxy)-5-[(tetrahydropyran-4-yl)oxy]quinazoline 525592-43-2P, 4-(3-Chloro-4-fluoroanilino)-7-[2-[N-(2-dimethylaminoethyl)-N-methylamino]ethoxy]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 525592-52-3P, 4-(3-Chloro-4-fluoroanilino)-7-[2-(3-dimethylaminopyrrolidin-1-yl)ethoxy]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 525592-57-8P, 4-(3-Chloro-4-fluoroanilino)-7-[3-[N-(2-dimethylaminoethyl)-N-methylamino]propoxy]-5-[(tetrahydrofuran-3-yl)oxy]quinazoline 525592-63-6P, 4-(3-Chloro-4-fluoroanilino)-7-

L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
[3-(3-dimethylaminopyrrolidin-1-yl)propoxy]-5-[(tetrahydrofuran-3-yl)oxy]quinazoline **525592-83-0P**, 4-(3-Chloro-4-fluoroanilino)-5-cyclopentyloxy-7-[3-(3-dimethylaminopyrrolidin-1-yl)propoxy]quinazoline **525592-94-3P**, 4-(3-Chloro-4-fluoroanilino)-5-cyclopentyloxy-7-[2-(3-dimethylaminopyrrolidin-1-yl)ethoxy]quinazoline
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor agent; prepn. of (anilino)quinazolines as erbB receptor tyrosine kinase inhibitors for treatment of cancer)

RN 525590-51-6 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-5-[(1-methyl-4-piperidinyl)oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 525592-03-4 CAPLUS
CN 1,2-Ethanediamine, N-[3-[[4-[(3-chloro-4-fluorophenyl)amino]-5-[(1-methyl-4-piperidinyl)oxy]-7-quinazolinyl]oxy]propyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)



RN 525592-14-7 CAPLUS
CN 1,2-Ethanediamine, N-[2-[[4-[(3-chloro-4-fluorophenyl)amino]-5-[(1-methyl-4-piperidinyl)oxy]-7-quinazolinyl]oxy]ethyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)



RN 525592-20-5 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-[2-[3-(dimethylamino)-1-pyrrolidinyl]ethoxy]-5-[(1-methyl-4-piperidinyl)oxy]- (9CI) (CA INDEX NAME)



RN 525592-29-4 CAPLUS
CN 1,2-Ethanediamine, N-[3-[[4-[(3-chloro-4-fluorophenyl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]propyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)

L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 525592-35-2 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-[3-[3-(dimethylamino)-1-pyrrolidinyl]propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 525592-43-2 CAPLUS
CN 1,2-Ethanediamine, N-[2-[[4-[(3-chloro-4-fluorophenyl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)



RN 525592-52-3 CAPLUS

L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-[2-[3-(dimethylamino)-1-pyrrolidinyl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 525592-57-8 CAPLUS
CN 1,2-Ethanediamine, N-[3-[[4-[(3-chloro-4-fluorophenyl)amino]-5-[(tetrahydro-3-furanyl)oxy]-7-quinazolinyl]oxy]propyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)



RN 525592-63-6 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-[3-[3-(dimethylamino)-1-pyrrolidinyl]propoxy]-5-[(tetrahydro-3-furanyl)oxy]- (9CI) (CA INDEX NAME)



L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 525592-83-0 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-5-(cyclopentyloxy)-7-[3-[3-(dimethylamino)-1-pyrrolidinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 525592-94-3 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-5-(cyclopentyloxy)-7-[2-[3-(dimethylamino)-1-pyrrolidinyl]ethoxy]- (9CI) (CA INDEX NAME)